NCT07804849RecruitingPhase 2/3
Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
Efficay and Safety of Oral Verapamil on Glycemic Metrics and ß-cell Reserve Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
Type 1 diabetes (T1D) in children involves autoimmune destruction of pancreatic ß- cells, leading to insulin deficiency. Verapamil is an L-type calcium channel blocker that has been used for decades to treat hypertension and certain cardiac conditions. Recent research has revealed its potential as a ß- cell-protective agent. Hence this study will evaluate the effect of once-daily oral verapamil on pancreatic ß- cell reserve , glycemic metrics and daily insulin requirements in children and adolescents with T1D.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 18 Aug 2026
- Start date
- 20 Aug 2026
- Primary completion date
- 20 Feb 2027
- Lead sponsor
- Ain Shams University
- Diseases
- Type 1 diabetes
- NCT number
- NCT07804849
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 70
- From 20 Aug 2026 to the primary completion date, 20 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of other endocrine disorders or autoimmune disorder (e.g. autoimmune thyroiditis).
Other illness
- Known allergy or intolerance to verapamil.
- Cardiac conduction abnormalities, heart block, or significant cardiac disease.
- Severe hepatic or renal impairment.
Lab values
- Current or planned use of medications that might affect glucose metabolism (e.g., corticosteroids, immunomodulators).
Age
- Systolic or diastolic blood pressure \< 5th percentile for age and gender.
Other
- Participation in another interventional clinical trial.
- Inability to follow the protocol for any reason as determined by the investigator.
- Elevated liver enzymes \>1.5 × upper limit of normal at screening
Who the study is looking for
- Children and adolescents aged 10-18 years.
- Newly diagnosed type 1 diabetes mellitus (within 6 weeks of diagnosis, defined as the day of starting insulin therapy).
- Presence of at least two positive islet autoantibody (anti glutamic acid decarboxylase antibodies, anti- tyrosine phosphataseantibodies ,anti- zinc transporter 8 protein antibodies , or anti-insulin antibodies).
- Ability to comply with study procedures.
Age in the registry: 10 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.